



Quince Therapeutics to Participate at Investor Events in December 2025

November 24, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 24, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025:

- Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, with a fireside chat beginning at 10:30 a.m. Eastern Time. Access to the company's fireside chat will be accessible on the Events page of Quince's Investor Relations website [here](#). An archive of the webcast will be available shortly following the end of the live event.
- Charles Ryan, J.D., Ph.D., Quince's President, will participate at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025. This event will include participation on a panel showcasing rare disease companies with key near-term, potentially stock-moving catalysts as Quince moves toward pivotal Phase 3 NEAT clinical trial topline results expected in the first quarter of 2026.
- Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, and Brendan Hannah, Quince's Chief Operating Officer and Chief Business Officer, will participate in a virtual Lunch with LifeSci Featuring Quince Therapeutics fireside chat hosted by LifeSci Advisors on Tuesday, December 16, 2025, beginning at 1:00 p.m. Eastern Time. Please register for the Lunch with LifeSci event [here](#).

About Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms [LinkedIn](#), [Facebook](#), [X](#), and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251124942104/en/): <https://www.businesswire.com/news/home/20251124942104/en/>

Media & Investor Contact:

Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Source: Quince Therapeutics, Inc.